Some notes from the AGM. Focus is on the new or the most important information. Company will be releasing a video soonish.
Takeaways / key-points
$1.7M cash (enough t0 get strategy started)
- Bisantrene is something very, very special ... consistently clears AML ...
- AML trial after trial after trial @ average ~ 50% complete response
- drugs have been approved by FDA at 21% complete response!
- unfortunately forgotten due to pharma mergers
- New strategy = 20-fold expansion in market opportunity
- Attract much larger partnership deal or takeover deal
- Can get early readout (1-2 months after treatment) on MRD = valuable for early approval or partnering
- Much lower risk of 5-path strategy
- Newsflow tempo of 5-path strategy
- Fast clinical outcomes from trials at much lower cost (trials focus in Australia), significant tax credits
- Volumes of Phase II and Phase III data will assist with approval
Robust commercial protection
Rare Paediatric Disease Designation
- Original patents had long expired so a new patent position was created (for use in AML, in other cancers and in combination)
- Once product is approved by FDA, RACE gets 7 years exclusivity (effectively as good as a patent)
- Expecting more patents from new strategy
Current path for AML is 7+3 induction chemotherapy plus stem cell transplant (requires a bone marrow transplant)
- Paediatric AML only 700 patients per year in US
- Incentive or “Golden Ticket” via Priority Review Voucher (for drug companies to develop drugs for rare diseases)
- Voucher grants 6-month accelerated review by FDA
- Can be sold to other companies ( USD $75M to $150M )
Daniel Tillett (CSO)
- Some patients aren’t well enough or fit for this treatment
- Treatment is not successful for everyone and some will relapse
- Background in biotech
- Due diligence systematically on every biotech company on the ASX
- Saw this chart (below) … thought wow! Something special.
- Consistently trial, after trial
- Complete response = tumor cleared!
- and in hard to treat relapse patients ... can actually cure
- Amazing that a drug like this is not on the market
- 2 french girls, went through many relapses, very, very ill and now still survive decades later after Bisantrene and bone marrow transplant
![]()
MRD Opportunity
Bisantrene combinations
- Bisantrene potentially the answer to remove residual cancer before Bone Marrow Transplant and significantly improve chances of survival
- Key opinion leaders very, very excited (could be major change for AML)
- 502 (b)(2) path allows historic data to back up case for accelerated approval ( reduced risk & time/effort )
- MRD can be measured ~ 1 month after treatment ( know early in treatment )
- can do multiple cycles (patients can tolerate Bisantrene)
Path 1 - MRD
- can decide in-vitro (in lab) which drugs Bisantrene works well with (can find synergy with other drugs in the market), potentially new treatment regimes
- can explore this potential in other cancers
Path 2 – Adult R/R AML
- Can use Phase II background data, don’t need to do Phase I trials (saves lots of time)
- Phase II approach to save money
- FDA now also approving drugs based on Phase II data (relatively small trials)
- Know MRD status within 1-2 mths of Bisantrene treatment
- Anything above a 10% improvement in survival generally approved
- FDA assesses safety based on Phase II data
Path 3 – Paediatric AML trial
- Relatively small trial (proof of concept to excite a partner)
Bisantrene stacks up very well against major chemo drug Doxorubicin (Bisantrane has lower cardiotoxicity).
- Lack of cardiotoxicity critical for children (Bisantrene doesn’t cause lifelong damage, Paediatricians excited by this)
Path 4 – Breast Cancer
Path 5
- The Blue Sky
- Some breast cancers are well-treated and some breast-cancers not well-treated
- Big issue with current breast cancer treatment is cardiotoxicity (younger women)
- Even with wrong dose historically Bisantrene still worked!
- Attract a partner following trials
New strategy is much, much cheaper and faster and lower risk (5 shots on goal), any pathway alone could be a company-maker (no binary outcome)
- Low-cost in-vitro (in the lab)
- Attract a partner following trials
ivosidenib suits only 8% of AML patients … sales US $300M per year …!
Bisantrene can be used on all AML cancers (not a targeted agent), hence much larger market
- Forums
- ASX - By Stock
- RAC
- Ann: Annual General Meeting Presentation
Ann: Annual General Meeting Presentation, page-22
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$2.02 |
Change
0.010(0.50%) |
Mkt cap ! $343.9M |
Open | High | Low | Value | Volume |
$2.04 | $2.09 | $1.92 | $768.4K | 380.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 484 | $2.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.02 | 3251 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 484 | 2.000 |
1 | 2319 | 1.985 |
1 | 252 | 1.980 |
1 | 16000 | 1.975 |
2 | 6132 | 1.970 |
Price($) | Vol. | No. |
---|---|---|
2.020 | 3251 | 2 |
2.040 | 500 | 1 |
2.050 | 10000 | 1 |
2.070 | 994 | 1 |
2.080 | 2450 | 1 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online